Piroxicam/β-Cyclodextrin

西地吡罗昔康

Report date: 2022/01/14 13:23:58

Base Information

Drug NamePiroxicam/β-Cyclodextrin
Drug Alias Nameβ-Cyclodextrin and Piroxicamβ-Cyclodextrin and Piroxicam
ClassificationSmall molecules
Mechanisms of ActionCyclooxygenases inhibitors
TargetsCyclooxygenases
Therapy Area/IndicationsOsteoarthritisArthritis, RheumatoidSpondylitis, Ankylosing
Global Approved IndicationsOsteoarthritisArthritis, RheumatoidSpondylitis, Ankylosing
Approved Indications in ChinaOsteoarthritisArthritis, RheumatoidSpondylitis, Ankylosing
Original Approved Country/TerritoryMainland China
Original Approved Date2013/12/02
Country/TerritoryMainland China
CombinationsYes Piroxicam
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesN/A
Active IndicationsOsteoarthritisArthritis, RheumatoidSpondylitis, Ankylosing
Inactive IndicationsN/A

Other Information

ATC CodeM01AC01M02AA07S01BC06
Related LinksN/A